News
07-08-2010, 03:12 AM
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies...
More... (http://mnt.to/f/3FPJ)
More... (http://mnt.to/f/3FPJ)